New cheaper eye drug shows promise against leading cause of blindness
NCT ID NCT04522167
Summary
This completed Phase 3 study tested whether a new, potentially more affordable biosimilar version of the drug aflibercept (FYB203) works as well and is as safe as the established drug Eylea for treating wet age-related macular degeneration (AMD). The study involved 434 patients with newly diagnosed wet AMD, who received injections of either the biosimilar or Eylea. Researchers measured changes in vision, eye health, and safety over 56 weeks to see if the two treatments were comparable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Sofia, Bulgaria
-
Research Site
Stara Zagora, Bulgaria
-
Research Site
Hradec Králové, Czechia
-
Research Site
Ostrava, Czechia
-
Research Site
Pardubice, Czechia
-
Research Site
Prague, Czechia
-
Research Site
Sokolov, Czechia
-
Research Site
Budapest, Hungary
-
Research Site
Debrecen, Hungary
-
Research Site
Pécs, Hungary
-
Research Site
Szeged, Hungary
-
Research Site
Székesfehérvár, Hungary
-
Research Site
Tatabánya, Hungary
-
Research Site
Zalaegerszeg, Hungary
-
Research Site
Haifa, Israel
-
Research Site
Jerusalem, Israel
-
Research Site
Kfar Saba, Israel
-
Research Site
Petah Tikva, Israel
-
Research Site
Rehovot, Israel
-
Research Site
Rishon LeZiyyon, Israel
-
Research Site
Tel Aviv, Israel
-
Research Site
Bologna, Italy
-
Research Site
Florence, Italy
-
Research Site
Milan, Italy
-
Research Site
Roma, Italy
-
Research Site
Rozzano, Italy
-
Research Site
Udine, Italy
-
Research Site
Akita, Japan
-
Research Site
Amagasaki, Japan
-
Research Site
Asahikawa, Japan
-
Research Site
Chiyoda City, Japan
-
Research Site
Chūō, Japan
-
Research Site
Fukuoka, Japan
-
Research Site
Fukushima, Japan
-
Research Site
Hamamatsu, Japan
-
Research Site
Himeji, Japan
-
Research Site
Hirakata, Japan
-
Research Site
Kita-ku, Japan
-
Research Site
Kurume, Japan
-
Research Site
Meguro City, Japan
-
Research Site
Nagasaki, Japan
-
Research Site
Nagoya, Japan
-
Research Site
Sapporo, Japan
-
Research Site
Shinjuku-Ku, Japan
-
Research Site
Suita, Japan
-
Research Site
Toride, Japan
-
Research Site
Yokosuka, Japan
-
Research Site
Bielsko-Biala, Poland
-
Research Site
Bydgoszcz, Poland
-
Research Site
Krakow, Poland
-
Research Site
Lodz, Poland
-
Research Site
Olsztyn, Poland
-
Research Site
Tarnów, Poland
-
Research Site
Warsaw, Poland
-
Research Site
Chelyabinsk, Russia
-
Research Site
Kazan', Russia
-
Research Site
Moscow, Russia
-
Research Site
Novosibirsk, Russia
-
Research Site
Saint Petersburg, Russia
-
Research Site
Kharkiv, Ukraine
-
Research Site
Kherson, Ukraine
-
Research Site
Kropyvnytskyi, Ukraine
-
Research Site
Lutsk, Ukraine
-
Research Site
Odesa, Ukraine
-
Research Site
Poltava, Ukraine
-
Research Site
Zaporizhzhya, Ukraine
Conditions
Explore the condition pages connected to this study.